Related Experiment Video
Updated: Apr 8, 2026

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
Published on: April 28, 2015
Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives
Matthew M Jones1, Amma A Boakye2, Nirali Dave3
1Department of Radiology and Imaging Sciences, Indiana University, 705 Riley Hospital Drive, Room 1053, Indianapolis, IN, 46202, USA. matmjone@iu.edu.
Insights
This review details safe use of gadolinium-based contrast agents (GBCAs) in pediatric MRI, addressing renal function and gadolinium retention risks. It offers strategies for risk mitigation and discusses alternatives like ferumoxytol.
Area of Science:
- Pediatric Radiology
- Pharmacology
- Nephrology
Background:
- Gadolinium-based contrast agents (GBCAs) are essential for pediatric MRI.
- Pediatric use necessitates caution due to immature renal function, gadolinium retention concerns, and risk of nephrogenic systemic sclerosis (NSF).
Purpose of the Study:
- To review GBCA molecular structure, pediatric pharmacokinetics, and adverse effects.
- To provide evidence-based strategies for safe GBCA administration in children.
- To discuss alternative contrast agents and future research needs.
Main Methods:
- Comprehensive literature review of GBCA safety and efficacy in pediatric populations.
- Synthesis of current evidence and guideline recommendations.
- Analysis of pediatric-specific pharmacokinetic data and adverse event profiles.
Main Results:
- Identified key risk factors for adverse events in children, including renal impairment.
- Outlined strategies for risk mitigation, such as agent selection based on eGFR and minimizing cumulative doses.
- Highlighted the potential of alternative agents like ferumoxytol for specific pediatric cases.
Conclusions:
- Judicious use of GBCAs in pediatric MRI requires careful patient selection and risk management.
- Adherence to evidence-based guidelines can optimize safety and efficacy.
- Further pediatric-specific research is crucial to refine contrast agent protocols.
Abstract:
Gadolinium-based contrast agents (GBCAs) are integral to pediatric magnetic resonance imaging (MRI), yet their use requires thoughtful consideration due to developmental differences in renal function, concerns about gadolinium retention, and the rare but serious risk of nephrogenic systemic sclerosis (NSF). This review summarizes current knowledge on GBCA molecular structure, pediatric-specific pharmacokinetics, and the spectrum of known adverse effects. We discuss practical, evidence-based strategies for risk mitigation, including identifying children at increased risk, avoiding group I and III agents when eGFR is <30 mL/min/1.73 m2 or kidney injury is suspected, minimizing cumulative lifetime exposure, and managing special populations such as neonates and children with prior allergic-like reactions. The review also outlines the growing role of alternative contrast agents, particularly ferumoxytol. By synthesizing current evidence and guideline recommendations, this article provides a comprehensive framework to support safe, effective, and judicious contrast-enhanced MRI in children while emphasizing areas where further pediatric-specific research is needed.
Related Concept Videos
Imaging Studies IV: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Radiological Investigation I: X-ray and CT
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies VII: Vascular Imaging

